Evaluating the Effect of Adipose Tissue Processed With the SyntrFuge™ System in the Healing of Diabetic Foot Ulcers

Trial statusNot yet recruiting
Trial phaseNot applicable
Trial typeInterventional
Biological sexAll
Age18-85
SponsorSyntr Health Technologies, Inc.

About this trial

This is a randomized controlled multi center study on diabetic patients with the aim of evaluating the efficacy of the adipose tissue processed with the SyntrFuge™ system in diabetic patients with diabetic foot ulcers. In particular, it will be evaluated whether the microsized fat graft will be able to shorten the healing times of these wounds. Patients will be randomized to the treatment group with adipose tissue processed with the SyntrFuge™ system (injection of autologous microsized adipose tissue) or to the control group represented by the standard of care.

Eligibility criteria

This trial does not accept healthy volunteers

Qualifiers

Subjects who have Diabetic Foot Ulcer located at the pad of the foot or the heel of the foot with a surface area range < 1 sq. cm to 25 sq. cm and < 5 cm in widest diameter on lower extremity, but larger than 1 sq. cm. Diabetics included will be those with HBA1C ≥ 6.5 % and ≤ 12%

Subjects with vascular problems absent or resolved (evaluated with Eco Color Doppler and ABI (Ankle Brachial Index, that calculates the ratio of the systolic pressure measured at the ankle and the systolic pressure in the arm, both measured in supine position using wave continue Doppler. If assessable, it has to be greater than/equal to .7) and pressure index finger/arm TBI (Toe Brachial Index, if assessable, it has to be greater than/equal to .6) and/or by the determination of the transcutaneous oxygen pressure (TcPO2 that needs to be equal to or greater than 30 mmHg)) or and alternative biphasic and triphasic waveforms, doppler waveform, or DP+PT

Subjects are ambulatory

Subjects aged 18 - 85

Disqualifiers

Subjects without decisional capacity

Subjects unable to give informed, written consent

Subjects with active infection (redness, swelling, pain, suppuration)

Subjects with osteomyelitis

Trial design

Design model

Parallel

Treatments tested in this trial

  • Syntrfuge Microfragmented Fat

    Device

    Microsized Adipose Tissue

  • Standard of Care

    Procedure/Surgery

    Debridement and Camboot

Treatment groups

62 Participants
are divided into 2 treatment groups
Group A: Syntrfuge Microfragmented FatExperimental treatment 1 intervention
Group B: Standard of CareOther 1 intervention

Trial outcomes

Primary outcomes

1

Full Wound Healing

The main study outcome will be time taken to achieve full wound closure, as determined by standard 12-week wound healing milestones defined by PERI and other clinical trials in this space

Time frame
12 weeks

Secondary outcomes

1

Safety of Intervention measured by number of Adverse and Significantly Adverse Events

Safety of SA (intervention) vs. the control group, as defined by the number of adverse events (all types) reported, the incidence of relapse, pain (assessed using the Visual Analog Scale \[VAS\] for pain), total time of hospitalization, total time of immobility, and comparisons of quality of life using the Short Form (SF-36) questionnaire.

Time frame
4 months

Other outcomes

Locations

This trial has no locations.

Sponsors and contacts

Click on the lead sponsor to view all of their trials.

This trial is not recruiting at the moment. You can still explore other options: